UNITED STATESSECURITIES AND ~~STATES~~EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-KCURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934Date of Report (Date of earliest event reported): May 12, 2017IASIS HEALTHCARE LLC(Exact name of registrant as specified in its charter)

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 8, 2017 (May 4, 2017)

IASIS HEALTHCARE LLC

(Exact name of registrant as specified in its charter)

Delaware

333-117362

20-1150104

(State or other jurisdiction of

organization)

(Commission File

Number)

(IRS Employer

Identification No.)

117 Seaboard Lane, Building E

Franklin, Tennessee

37067

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (615) 844-~~2747~~2747Not Applicable(Former name or former address, if changed since last report)

~~Not~~ Check ~~Applicable~~the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~(Former~~ ⃞ Written communications ~~name~~pursuant orto ~~former~~Rule ~~address,~~425 ifunder ~~changed~~the ~~since~~Securities ~~last~~Act ~~report)~~(17 CFR 230.425)

~~Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933~~ ~~(§ 230.405~~ ⃞ Soliciting material ofpursuant ~~this~~to ~~chapter) or~~ Rule ~~12b~~14a-212 ofunder the ~~Securities~~ Exchange Act ~~of 1934~~ (§ 17 CFR 240.~~12b~~14a-~~2 of this chapter~~12).

~~Emerging~~ ⃞ Pre-commencement communications ~~growth~~pursuant ~~company ☐~~to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

~~If an emerging~~ ~~growth~~ ⃞ Pre-commencement communications ~~company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided~~ pursuant to ~~Section~~Rule 1313e-4(ac) ofunder the Exchange Act~~. ☐~~ (17 CFR 240.13e-4(c))

~~Check~~ Indicate ~~the~~by ~~appropriate~~check ~~box~~mark ~~below~~whether if the ~~Form~~registrant ~~8-K filing~~ is ~~intended~~an toemerging ~~simultaneously~~growth ~~satisfy~~ company ~~the~~as ~~filing~~defined ~~obligation~~in Rule 405 of the ~~registrant~~Securities ~~under~~Act ~~any~~of 1933 (§230.405 of ~~the~~this ~~following~~chapter) ~~provisions~~or ~~(see~~Rule ~~General~~12b-2 ~~Instructions~~of Athe Securities Exchange Act of 1934 (§240.12b-2. ~~below):~~of this chapter).

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Emerging growth company	⃞

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.	⃞

☐Item ~~Soliciting~~2.02. ~~material~~Results ~~pursuant~~of toOperations ~~Rule~~and ~~14a-12~~Financial ~~under the Exchange Act (17 CFR 240~~Condition.~~14a-12)~~

☐ The information ~~Pre-commencement~~in ~~communications~~this Report, including the Exhibit attached hereto, is furnished pursuant to ~~Rule~~Item ~~14d-~~2.02 of this Form 8-K. Consequently, it is not deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (bthe “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act ~~(17~~or ~~CFR~~Securities ~~240.14d~~Act of 1933 if such subsequent filing specifically references this Form 8-~~2(b))~~K.

☐ On ~~Pre-commencement~~May ~~communications~~12, ~~pursuant~~2017, toIASIS ~~Rule~~Healthcare ~~13e-4~~LLC (cthe “Company”) issued ~~under~~a press release announcing its results for the ~~Exchange~~fiscal ~~Act~~second quarter ~~(17~~and ~~CFR~~six ~~240~~months ended March 31, 2017.~~13e-4(c))~~ For information regarding the results, reference is made to the press release dated May 12, 2017, and certain supplemental financial information, which are attached hereto as Exhibit 99.1 and incorporated herein by reference.

~~Item~~ The 1press release contains non-GAAP financial measures.01 For ~~Entry~~purposes ~~into~~of Regulation G, a ~~Material~~non-GAAP ~~Definitive~~financial ~~Agreement~~measure is a numerical measure of a registrant’s historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measure calculated and presented in accordance with GAAP in the statement of income, balance sheet or statement of cash flows (or equivalent statements) of the issuer or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measure so calculated and presented. In this regard, GAAP refers to generally accepted accounting principles in the United States. Pursuant to the requirements of Regulation G, the Company has provided reconciliations within the press release of the non-GAAP financial measures to the most directly comparable GAAP financial measures

~~Term~~ Adjusted ~~Loan~~EBITDA ~~Amendment~~and normalized adjusted EBITDA are each non-GAAP financial measures. Adjusted EBITDA represents net earnings (loss) from continuing operations before net interest expense, income tax expense (benefit), depreciation and amortization, stock-based compensation, gain on disposal of assets, and management fees. Management fees represent monitoring and advisory fees paid to management companies affiliated with TPG and JLL. Normalized adjusted EBITDA represents adjusted EBITDA before losses associated with the Company’s Arizona health insurance marketplace exchange plan, IT conversion related costs, EHR settlements related to prior years, initial public offering, advisory and other legal and regulatory cost and costs associated with systems improvement efforts at the Company’s Houston operations. Management routinely calculates and communicates adjusted EBITDA and believes that it is useful to investors because it is commonly used as an analytical indicator within the healthcare industry to evaluate performance, allocate resources and measure leverage capacity and debt service ability. In addition, the Company uses adjusted EBITDA as a measure of financial and operating performance for its business segments and on a consolidated basis and for incentive compensation purposes. In addition, management believes that the presentation of normalized adjusted EBITDA assists investors in evaluating the Company’s ongoing operational performance by excluding the impact of certain items that the Company believes may not be reflective of underlying business performance. Neither adjusted EBITDA nor normalized adjusted EBITDA should be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from such measures are significant components in understanding and assessing financial performance. Neither adjusted EBITDA nor normalized adjusted EBITDA should be considered in isolation or as an alternative to net earnings, cash flows generated by operating, investing, or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. Adjusted EBITDA and normalized adjusted EBITDA, as presented, differ from “adjusted EBITDA” as defined under the Company’s senior secured credit agreements and may not be comparable to similarly titled measures of other companies. A table describing adjusted EBITDA and normalized adjusted EBITDA and reconciling net earnings (loss) from continuing operations to adjusted EBITDA and normalized adjusted EBITDA is included later in the press release in the attached Supplemental Consolidated Statements of Operations Information.

OnItem ~~May 4, 2017, IASIS Healthcare LLC (the “Company”), IASIS Healthcare Corporation (“Holdings”), certain of their subsidiaries, the lenders party thereto, JPMorgan Chase Bank, N~~9.A01., asFinancial ~~the~~Statements ~~Additional Term B-3 Lender (as defined therein), Wilmington Trust, National Association, as administrative agent (the “Term Agent”),~~ and ~~the other agents named therein entered into an Amendment No~~Exhibits. 4 (“Term Amendment No. 4”) to the Amended and Restated Credit Agreement, dated as of May 3, 2011, as amended as of February 17, 2016, among the Company, Holdings, the Term Agent, and each lender from time to time party thereto (as further amended by Term Amendment No. 4, the “Amended and Restated Credit Agreement” and the facility provided thereunder, the “Term Loan Facility”).

~~Pursuant to Term Amendment No. 4, all of the then-outstanding term loans under the Amended and Restated Credit~~ ~~Agreement were refinanced with term loans~~ (~~the “Term B-3 Loans”~~d) ~~maturing on February 17, 2021, subject to, if earlier, a springing maturity date of 91 days prior to the maturity date of the 8~~ Exhibits.375% senior notes due 2019 (the “Senior Notes”) issued pursuant to the Company’s Indenture, dated as of May 3, 2011, by and among the Company, Holdings and The Bank of New York Mellon Trust Company, N.A., as Trustee (the “Indenture”), if any of the Senior Notes remains outstanding as of such date. The interest rate margins applicable to the Term B-3 Loans are 4.00%, for LIBOR-based loans, and 3.00%, for base rate loans, with a LIBOR floor of 1.25%. Term Amendment No. 4 also provides for a soft call prepayment premium applicable to certain repricing transactions involving the outstanding Term B-3 Loans. The soft call premium equals 1% of the amount of the Term B-3 Loans that are subject to certain repricing transactions occurring on or prior to May 4, 2018.

~~In addition, certain of the baskets available to the Company under the negative covenants in its Amended and Restated Credit Agreement are~~ ~~suspended~~ 99.1 Press ~~under~~Release ~~the~~dated ~~Amended~~May ~~and Restated Credit Agreement until such time~~12, ~~if any~~2017, ~~as the Company has consummated a qualifying underwritten public offering~~ and supplemental ~~achieved~~financial ~~a specified total gross leverage ratio~~information.

~~The foregoing description of Term Amendment No. 4 and the Amended and Restated Credit Agreement is a general description and is qualified~~ ~~in its entirety by reference to the full text of Term Amendment No. 4, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.~~ 2

~~Revolver Amendment.~~ SIGNATURES

On Pursuant ~~May 4, 2017, the Company, Holdings, the lenders party~~ to the ~~Existing~~requirements ~~Revolving Credit Agreement (as defined below) as~~ of ~~such date, JPMorgan Chase Bank, N.A., as administrative agent (~~the ~~“Revolver~~Securities ~~Agent”),~~Exchange ~~and~~Act ~~the~~of ~~other agents named therein~~1934, ~~entered into an amendment (“Revolver Amendment No. 1”) to~~ the ~~Revolving Credit Agreement, dated as of~~registrant ~~February 17,~~ has ~~2016~~duly ~~(the~~caused ~~“Existing~~this ~~Revolving~~report ~~Credit~~to ~~Agreement”~~be ~~and,~~signed ~~the~~on ~~Existing~~its ~~Revolving~~behalf ~~Credit Agreement, as amended~~ by ~~Revolver Amendment No. 1,~~ the ~~“Revolving Credit Agreement”), among the Company, Holdings, the~~ ~~lenders~~ undersigned ~~party~~hereunto ~~thereto~~duly ~~and the Revolver Agent~~authorized.

Pursuant to Revolver Amendment No. 1, the loans under the Revolving Credit Agreement mature in February 2021 (the “Stated Revolver Maturity Date”), provided that, if prior to the Stated Revolver Maturity Date, (x) any loans are outstanding under the Term Loan Facility on the date that is 91 days prior to the maturity date of at least $100 million of loans under the Term Loan Facility (such date, the “Springing Term Maturity Date”) or (y) any Senior Notes are outstanding under the Indenture on the date that is 91 days prior to the maturity date under the Indenture (such date, the “Springing Notes Maturity Date”), then the maturity date will automatically become the earlier of the Springing Term Maturity Date or the Springing Notes Maturity Date.

		IASIS HEALTHCARE LLC


		By:	/s/ John M. Doyle
			John M. Doyle
			Chief Financial Officer

Date:	May 12, 2017

~~The foregoing description of Revolver Amendment No. 1 and the Revolving Credit Agreement is a general description and is qualified in its~~ ~~entirety by reference to the full text of Revolver Amendment No. 1, which is filed as Exhibit 10.2 to this Current Report on Form 8-K and incorporated herein by reference.~~ 3

~~Item~~ EXHIBIT ~~2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.~~INDEX

The information set forth in Item 1.01 is incorporated by reference into this Item 2.03.

No.		Exhibit
99.1		Press Release dated May 12, 2017, and supplemental financial information.

~~Item 9.01. Financial Statements and Exhibits.~~ 4

Exhibit		Description
10.1		Amendment No. 4, dated as of May 4, 2017, among IASIS Healthcare LLC, IASIS Healthcare Corporation and the other guarantors party thereto, the lenders party thereto, Wilmington Trust, National Association, as administrative agent, and JPMorgan Chase Bank, N.A., as the Additional Term B-3 Lender (as defined therein) and attached thereto as Exhibit A, the Amended and Restated Credit Agreement, dated as of May 3, 2011 as amended as of May 4, 2017, among IASIS Healthcare LLC, IASIS Healthcare Corporation, Wilmington Trust, National Association, as administrative agent and collateral agent, and each lender from time to time party thereto.
10.2		Amendment No. 1, dated as of May 4, 2017, among IASIS Healthcare LLC, IASIS Healthcare Corporation and the other guarantors party thereto, the lenders as of the date thereof and JPMorgan Chase Bank, N.A., as administrative agent, and attached thereto as Exhibit A, the Revolving Credit Agreement, dated as of February 17, 2016 as amended as of May 4, 2017, among IASIS Healthcare LLC, IASIS Healthcare Corporation, JPMorgan Chase Bank, N.A., as administrative agent, swing line lender and L/C Issuer and each lender from time to time party thereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX

Exhibit		Description
10.1		Amendment No. 4, dated as of May 4, 2017, among IASIS Healthcare LLC, IASIS Healthcare Corporation and the other guarantors party thereto, the lenders party thereto, Wilmington Trust, National Association, as administrative agent, and JPMorgan Chase Bank, N.A., as the Additional Term B-3 Lender (as defined therein) and attached thereto as Exhibit A, the Amended and Restated Credit Agreement, dated as of May 3, 2011 as amended as of May 4, 2017, among IASIS Healthcare LLC, IASIS Healthcare Corporation, Wilmington Trust, National Association, as administrative agent and collateral agent, and each lender from time to time party thereto.
10.2		Amendment No. 1, dated as of May 4, 2017, among IASIS Healthcare LLC, IASIS Healthcare Corporation and the other guarantors party thereto, the lenders as of the date thereof and JPMorgan Chase Bank, N.A., as administrative agent, and attached thereto as Exhibit A, the Revolving Credit Agreement, dated as of February 17, 2016 as amended as of May 4, 2017, among IASIS Healthcare LLC, IASIS Healthcare Corporation, JPMorgan Chase Bank, N.A., as administrative agent, swing line lender and L/C Issuer and each lender from time to time party thereto.

IASIS HEALTHCARE LLC

/s/ John M. Doyle

John M. Doyle

Chief Financial Officer

Date: May 8, 2017

Filing Compare · IASIS Healthcare LLC